The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 4)
Target Validation, 2015
Numerous studies have highlighted a potential role of neuroinflammation in Parkinson's disease whereby the immune cells of the brain called microglia may produce inflammatory factors that are toxic to dopamine neurons. Cannabinoid type-2 receptors (CB2) are largely found on activated microglia and are increased in people with and models of Parkinson's disease. Th...
Therapeutic Pipeline Program, 2014
Speech and voice disorders are common in people with Parkinson's disease (PD) and adversely affect their communication and quality of life. Presently, Lee Silverman Voice Treatment (LSVT) is the most effective treatment available for speech disorders in PD, but this program is time intensive. Transcranial magnetic stimulation (TMS) is a safe and non-invasive, com...
Researchers: Shalini Narayana, MBBS, PhD
Rapid Response Innovation Awards, 2007
A pre-clinical model of Parkinson's disease can be generated by injecting MPTP, a toxin that results in specific damage to the same part of the brain that is damaged in Parkinson's disease. The proposed experiments will examine the effects of this toxin in mice with full or partial elimination of GD3S. mice will first be assessed on a batter of behavioral tasks designed to ass...
Researchers: Michael P. McDonald,
Community Fast Track, 2007
Gene Therapy for Parkinson's Disease: Does Re-expression of HCN2 in GPe Improve Motor Deficits in Rodent PD Model?
Promising Outcomes of Original Grant:
We hypothesized that dopamine depletion in Parkinson’s disease results in downregulation of a specific ion channel, termed HCN2, in neurons of the external segment of the globus pallidus (GPe); we proposed that this loss of HCN2 is sufficient to trigger and perpetuate pathological activity in the synaptic circuit of GPe and subthalamic nucleus (STN), which is...
Researchers: Pavel Osten, MD, PhD